Mashup Score:18
OncLiveFDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer - 4 days
Mashup Score:18
Twitter Feed: OncLive.com
Mashup Score:12
OncLiveMridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...
-
Adjuvant trastuzumab emtansine plus concurrent radiation therapy did not result in cardiotoxicities in patients with early-stage HER2-positive breast cancer. @MridulaGeorgeMD @RWJBarnabas #bcsm #oncology https://t.co/Id3kQqgT9D https://t.co/Id3kQqgT9D - view on twitter
Mashup Score:9
OncLiveBreast Cancer Expert Focuses on Decoding Biomarkers - 5 days
Mashup Score:9
For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on...
-
Breast Cancer Expert Focuses on Decoding Biomarkers @KalinskyKevin @jhaveri_komal @jane_meisel @YAbdouMD @jsparano @WinshipAtEmory @MSKCancerCenter @UNC_Lineberger @TischCancer #bcsm https://t.co/6FGIBFkUQI - view on twitter
More coverage:
#bcsm
Mashup Score:9
OncLiveImmunotherapy Propels Urothelial Carcinoma Treatment Advances - 5 days
Mashup Score:9
Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...
-
Immunotherapy Propels Urothelial Carcinoma Treatment Advances @bergsa83 @DanaFarber #oncology #medtwitter https://t.co/ppwU4exk32 - view on twitter
Mashup Score:8
OncLiveNeoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors - 1 week
Mashup Score:8
Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...
-
Neoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors @MDAndersonNews @JCO_ASCO #oncology #MedTwitter https://t.co/hUZmQlPoFw - view on twitter
Mashup Score:8
OncLiveMutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC - 1 day
Mashup Score:8
Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...
-
PARP inhibitors as monotherapies or in combination with AR pathway inhibitors may broaden treatment options for patients with mCRPC) with gene alterations within the homologous recombination–deficient pathwa. @DanaFarber #pcsm #oncology https://t.co/rr5t2dPC03 https://t.co/rr5t2dPC03 - view on twitter
Mashup Score:8
OncLiveKEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility - 1 week
Mashup Score:8
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...
-
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility. #pcsm #oncology https://t.co/H4O4P0WVwn https://t.co/H4O4P0WVwn - view on twitter
Mashup Score:7
OncLiveCombinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment - 4 days
Mashup Score:7
Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and...
-
Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment @UPMCHillmanCC @OncLiveSOSS #lcsm #OncLiveIPC https://t.co/EdyPzDfAN7 - view on twitter
Mashup Score:6
OncLiveMridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...
-
Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer @MridulaGeorgeMD @RutgersCancer @RWJMS @SABCSSanAntonio #bcsm #SABCS22 https://t.co/qGRnx9d7Qg https://t.co/qGRnx9d7Qg - view on twitter
Mashup Score:6
OncLiveZolbetuximab Plus Chemo Extends PFS and OS in CLDN18.2+ Metastatic Gastric Cancer - 1 week
Mashup Score:6
Zolbetuximab demonstrated a survival benefit and a tolerable safety profile when combined with mFOLFOX6 vs mFOLFOX6 plus placebo in patients with CLDN18.2-positive, HER2-negative locally...
-
Zolbetuximab demonstrated a survival benefit when combined w/ mFOLFOX6 vs mFOLFOX6 + placebo in CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. @KoheiShitara #oncology https://t.co/bVbJF79yUs - view on twitter
More coverage:
#oncology
The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...
BREAKING: @US_FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer #bcsm #oncology https://t.co/n4ZkhKiFB0 https://t.co/n4ZkhKiFB0 - view on twitter